Gawlik-Kotelnicka Oliwia, Strzelecki Dominik
Department of Affective and Psychotic Disorders, Medical University of Lodz, 90-419 Lodz, Poland.
Pharmaceuticals (Basel). 2021 Apr 20;14(4):384. doi: 10.3390/ph14040384.
Depression and metabolic diseases often coexist, having several features in common, e.g., chronic low-grade inflammation and intestinal dysbiosis. Different microbiota interventions have been proposed to be used as a treatment for these disorders. In the paper, we review the efficacy of probiotics in depressive disorders, obesity, metabolic syndrome and its liver equivalent based on the published experimental studies, clinical trials and meta-analyses. Probiotics seem to be effective in reducing depressive symptoms when administered in addition to antidepressants. Additionally, probiotics intake may ameliorate some of the clinical components of metabolic diseases. However, standardized methodology regarding probiotics use in clinical trials has not been established yet. In this narrative review, we discuss current knowledge on the recently used methodology with its strengths and limitations and propose criteria that may be implemented to create a new study of the effectiveness of probiotics in depressive disorders comorbid with metabolic abnormalities. We put across our choice on type of study population, probiotics genus, strains, dosages and formulations, intervention period, as well as primary and secondary outcome measures.
抑郁症和代谢性疾病常常并存,具有一些共同特征,例如慢性低度炎症和肠道菌群失调。人们已经提出了不同的微生物群干预措施用于治疗这些疾病。在本文中,我们基于已发表的实验研究、临床试验和荟萃分析,综述了益生菌在抑郁症、肥胖症、代谢综合征及其肝脏等效病症中的疗效。除抗抑郁药外,服用益生菌似乎对减轻抑郁症状有效。此外,摄入益生菌可能会改善代谢性疾病的一些临床症状。然而,尚未建立关于益生菌在临床试验中使用的标准化方法。在这篇叙述性综述中,我们讨论了当前关于最近使用的方法的知识及其优缺点,并提出了一些标准,这些标准可用于开展一项新的研究,以评估益生菌对合并代谢异常的抑郁症的疗效。我们阐述了我们对研究人群类型、益生菌属、菌株、剂量和配方、干预期以及主要和次要结局指标的选择。